Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Migra3
- Development stage
- Unknown
- Administration
- Oral
01
Overview
Migra3 is a dietary supplement formulated for the dietetic treatment of migraine patients. It contains a combination of Coenzyme Q10, Vitamin B1 (Thiamine), Vitamin B2 (Riboflavin), Nicotinamide (Vitamin B3), Pantothenic acid (Vitamin B5), Vitamin B6, Vitamin B12, and Folic acid. These ingredients are known to play roles in cellular energy production, antioxidant defense, and various metabolic pathways crucial for neurological health, which are often implicated in the pathophysiology of migraines.
- Brand names
- Migra3Migra-3Migra 3
- Other names
- Migra 3Migra3Migra-3
02
Targets
ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on Migra3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Migra3.